Successful immunotherapy for Triatoma protracta-induced anaphylaxis.
A successful program of immunotherapy for Triatoma protracta-induced anaphylaxis was developed. This program included a new passive extract-antigen preparation standardized by RAST inhibition. This antigen facilitated the development of a reliable skin test protocol for in vivo diagnosis of Triatoma protracta allergy. Five patients with T. protracta-induced anaphylaxis underwent a rapidly increasing dosage schedule of immunotherapy. The IgE- and IgG-antibody responses during immunotherapy were followed with solid-phase RIA. Protection against anaphylaxis was confirmed in all patients with a "bite challenge" by T. protracta. This is the first report of completely successful T. protracta immunotherapy.
D000328:Adult; D000707:Anaphylaxis / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D000941:Antigens / Q000008:administration & dosage / Q000302:isolation & purification / Q000592:standards; D005247:Feeding Behavior; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007299:Insect Bites and Stings / Q000150:complications* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012882:Skin Tests; D014224:Triatoma / Q000276:immunology* / Q000502:physiology; D014225:Triatominae / Q000276:immunology*
D000941:Antigens